Coramitug for Transthyretin Amyloid Cardiomyopathy
(CLEOPATTRA Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if the new medicine NNC6019-0001 (also known as Coramitug) can reduce the risk of heart-related problems in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM), a condition affecting the heart. Participants will receive either the medicine or a placebo (a treatment with no active ingredients) while continuing their regular heart treatments. Suitable candidates for this trial include individuals with ATTR-CM experiencing heart issues such as shortness of breath or leg swelling. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to potentially groundbreaking treatment advancements.
Do I have to stop taking my current medications for the trial?
The trial does not require you to stop your current heart medications. You should continue your usual heart treatments as recommended by your doctor.
Is there any evidence suggesting that NNC6019-0001 is likely to be safe for humans?
In a previous study, patients who took NNC6019-0001, a new medicine for transthyretin amyloid cardiomyopathy (ATTR-CM), generally tolerated it well, with most not reporting serious side effects. Research has shown that this treatment is a humanized monoclonal antibody, which helps remove harmful proteins from the heart. This might explain its general tolerability. Another study found no major safety issues over a longer period, suggesting it is safe for many people. However, like any medicine, some might experience mild side effects. Always discuss potential risks with a doctor.12345
Why do researchers think this study treatment might be promising?
Coramitug, or NNC6019-0001, is unique because it represents a new experimental approach to treating transthyretin amyloid cardiomyopathy (ATTR-CM), a condition typically managed by stabilizing the transthyretin (TTR) protein or reducing its production. Unlike current treatments like tafamidis, which stabilize the TTR protein, NNC6019-0001 is administered intravenously and is designed to target and remove the amyloid deposits that cause damage to the heart. This direct action on amyloid deposits offers a potentially transformative way to address the root cause of heart problems in ATTR-CM, which is why researchers are particularly excited about its potential impact.
What evidence suggests that NNC6019-0001 might be an effective treatment for ATTR-CM?
Research shows that NNC6019-0001, which participants in this trial may receive, may help treat transthyretin amyloid cardiomyopathy (ATTR-CM), a heart condition. In earlier studies, this antibody drug helped remove harmful protein deposits called amyloids from the heart and other organs. These amyloid deposits can damage tissues. By reducing these deposits, NNC6019-0001 might improve heart function and lower the risk of heart problems. Initial results from other trials showed that this treatment is safe and well-tolerated by patients, suggesting NNC6019-0001 could be an effective option for managing ATTR-CM.36789
Who Is on the Research Team?
Clinical Transparency (dept. 2834)
Principal Investigator
Novo Nordisk A/S
Are You a Good Fit for This Trial?
This trial is for individuals with transthyretin amyloid cardiomyopathy (ATTR-CM), a condition that affects the heart. Participants must be currently receiving standard treatments for heart failure and are willing to add either the study drug or placebo to their regimen.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either NNC6019-0001 or placebo intravenously, alongside their standard of care treatments
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- NNC6019-0001
Trial Overview
The CLEOPATTRA study is testing NNC6019-0001, a new medication, against a placebo. The goal is to see if it can lower the risk of heart-related death and illness in ATTR-CM patients. Treatment assignment is random.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Participants will receive NNC6019-0001 intravenously (IV). Participants will also have the option to continue any Standard of care (SoC) treatments as recommended by their medical health professional.
Participants will receive placebo matched to NNC6019-0001 IV. Participants will also have the option to continue any SoC treatments as recommended by their medical health professional.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novo Nordisk A/S
Lead Sponsor
Lars Fruergaard Jørgensen
Novo Nordisk A/S
Chief Executive Officer since 2017
MSc in Finance and Business Administration, Aarhus School of Business, Aarhus University, Denmark
Martin Holst Lange
Novo Nordisk A/S
Chief Medical Officer since 2021
MD from University of Copenhagen
Citations
NCT06260709 | A Research Study to Look at Long-term ...
This study will test a medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis. It will look at how safe this medicine is in the long ...
2.
sciencehub.novonordisk.com
sciencehub.novonordisk.com/content/sciencehub/global/en/congresses-and-scientific-publications/congresses/aha2025/fontana.htmlAHA 2025 - Primary results from the phase 2 randomized ...
Primary results from the phase 2 randomized, placebo controlled, blinded trial of the monoclonal antibody coramitug in transthyretin amyloid cardiomyopathy ...
Current and Future Treatment Landscape of Transthyretin ...
Preclinical studies showed effective amyloid clearance across multiple organs, including the heart, liver, and spleen, with sustained phagocytic ...
ATTR CM: Efficacy and Safety of NNC6019-0001 in ...
The purpose of this study is to determine whether an investigational drug called NNC6019-0001 can be used to treat people with transthyretin (TTR)
A Research Study to Look at the Effects of Treatment ...
This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition ...
Coramitug, a Humanized Monoclonal Antibody for the ...
Coramitug is a humanized monoclonal antibody that targets misfolded transthyretin, designed to promote clearance of transthyretin amyloid ...
NCT05442047 | A Research Study to Look at How a New ...
This study is testing a potential new medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis.
Long-Term Safety and Efficacy of NNC6019-0001 in ...
The purpose of this study is to evaluate the long-term safety and effectiveness of a medicine called NNC6019-0001 in people who have heart failure.
NNC6019–0001, a humanized monoclonal antibody, in ...
This is a randomized, double-blind, placebo-controlled trial recruiting 99 patients with hereditary or wild-type ATTR-CM.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.